secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210310
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Q1 net loss $53.5M, cash $147M; navacaprant data on track for Q2 2026
-----------------------------------------------------------------------------

- Net loss of $53.5M for Q1 2026, improved from $68.0M in Q1 2025.
- Cash and cash equivalents $147.1M as of March 31, 2026; expected to fund operations into Q3 2027.
- KOASTAL-2 and -3 fully enrolled with >400 patients each; joint topline readout expected in Q2 2026.
- NMRA-511 Phase 1b showed effect in Alzheimer’s agitation; MAD expansion data in H2 2026, Phase 2 planned Q1 2027.
- NMRA-898 Phase 1 data in stable schizophrenia expected H2 2026; NMRA-215 preclinical update also in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526210310/0001193125-26-210310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526210310/nmra-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer